Home
About
Overview
Sharing Data
ORCID
Help
History (26)
Mental Navigation Tests
INFLAMMATORY MEDIATORS IN ALLERGIC RHINITIS
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
Macleod, Kay
Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias.
See All 26 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias.
Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias. Front Immunol. 2025; 16:1558275.
View in:
PubMed
subject areas
Humans
Immunoglobulin Light-chain Amyloidosis
Immunotherapy, Adoptive
Leukemia, Plasma Cell
Paraproteinemias
Treatment Outcome
authors with profiles
Benjamin Derman